[New therapeutic targets and strategies in lung cancer].
Sánchez De Cos Escuín
J
J
Unidad de Neumología, Hospital San Pedro de Alcántara, Cáceres, Spain.
D019883:Alkyl and Aryl Transferases / Q000037:antagonists & inhibitors; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D001569:Benzodiazepines / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D016228:Endothelial Growth Factors / Q000037:antagonists & inhibitors / Q000276:immunology; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D004815:Epidermal Growth Factor / Q000037:antagonists & inhibitors*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D000069347:Erlotinib Hydrochloride; D051231:Farnesyltranstransferase; D000077156:Gefitinib; D006801:Humans; D000068877:Imatinib Mesylate; D007093:Imidazoles / Q000627:therapeutic use; D036341:Intercellular Signaling Peptides and Proteins / Q000276:immunology; D008175:Lung Neoplasms / Q000188:drug therapy*; D008222:Lymphokines / Q000037:antagonists & inhibitors / Q000276:immunology; D008666:Metalloendopeptidases / Q000037:antagonists & inhibitors; D015337:Multicenter Studies as Topic; D010879:Piperazines; D011106:Polyisoprenyl Phosphates / Q000378:metabolism; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011743:Pyrimidines / Q000627:therapeutic use*; D011799:Quinazolines / Q000627:therapeutic use*; D015363:Quinolones / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D012717:Sesquiterpenes; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D001549:Benzamides; D016228:Endothelial Growth Factors; D004791:Enzyme Inhibitors; D007093:Imidazoles; D036341:Intercellular Signaling Peptides and Proteins; D008222:Lymphokines; D010879:Piperazines; D011106:Polyisoprenyl Phosphates; D011743:Pyrimidines; D011799:Quinazolines; D015363:Quinolones; D012717:Sesquiterpenes; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D001569:Benzodiazepines; D004815:Epidermal Growth Factor; C004808:farnesyl pyrophosphate; D000068877:Imatinib Mesylate; D000069347:Erlotinib Hydrochloride; D019883:Alkyl and Aryl Transferases; D051231:Farnesyltranstransferase; D066246:ErbB Receptors; D011505:Protein-Tyrosine Kinases; D020794:Receptor Protein-Tyrosine Kinases; D008666:Metalloendopeptidases; C415151:7-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine; C402769:tipifarnib; D000077156:Gefitinib